Resmed Historical Cash Flow
| RMD Stock | 38.19 0.13 0.34% |
Analysis of Resmed cash flow over time is an excellent tool to project Resmed Inc DRC future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 325.3 M or Depreciation of 227 M as it is a great indicator of Resmed ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Resmed Inc DRC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Resmed Inc DRC is a good buy for the upcoming year.
Resmed |
About Resmed Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Resmed balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Resmed's non-liquid assets can be easily converted into cash.
Resmed Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Resmed's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Resmed Inc DRC current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Resmed's End Period Cash Flow is comparatively stable compared to the past year. Net Borrowings is likely to gain to about 803 M in 2024, whereas Capital Expenditures is likely to drop slightly above 66.9 M in 2024.
| 2020 | 2022 | 2023 | 2024 (projected) | Dividends Paid | 245.3M | 258.3M | 282.3M | 205.5M | Stock Based Compensation | 65.3M | 71.1M | 80.2M | 41.0M |
Resmed cash flow statement Correlations
Click cells to compare fundamentals
Resmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Resmed cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (69.9M) | (22.0M) | (311.7M) | (248.8M) | 172.2M | 180.8M | |
| Change In Cash | 316.0M | (167.9M) | (21.6M) | (45.8M) | 10.5M | 6.0M | |
| Free Cash Flow | 696.3M | 619.9M | 195.1M | 559.3M | 1.3B | 1.4B | |
| Change In Working Capital | (97.9M) | 1.4M | (708.1M) | (462.1M) | 44.8M | 47.0M | |
| Begin Period Cash Flow | 147.1M | 463.2M | 295.3M | 273.7M | 227.9M | 325.3M | |
| Other Cashflows From Financing Activities | (46.4M) | (53.7M) | (52.4M) | (33.0M) | (10.1M) | (10.6M) | |
| Depreciation | 181.4M | 191.5M | 193.8M | 197.6M | 216.2M | 227.0M | |
| Other Non Cash Items | (7K) | 8.7M | 20.7M | (11.1M) | 39.1M | 41.1M | |
| Capital Expenditures | 105.9M | 116.8M | 156.0M | 134M | 114.9M | 66.9M | |
| Total Cash From Operating Activities | 802.3M | 736.7M | 351.1M | 693.3M | 1.4B | 1.5B | |
| Net Income | 621.7M | 474.5M | 779.4M | 897.6M | 1.0B | 1.1B | |
| End Period Cash Flow | 463.2M | 295.3M | 273.7M | 227.9M | 238.4M | 333.5M | |
| Sale Purchase Of Stock | (50.2M) | 90M | 288M | (30.6M) | (150.0M) | (142.5M) | |
| Stock Based Compensation | 57.6M | 63.9M | 65.3M | 71.1M | 80.2M | 41.0M | |
| Dividends Paid | 225.1M | 226.7M | 245.3M | 258.3M | 282.3M | 205.5M | |
| Change To Account Receivables | 54.4M | (129.2M) | 19.3M | (106.5M) | (134.3M) | (127.6M) | |
| Investments | (31.6M) | (21.8M) | (13.9M) | (1.2B) | (269.8M) | (283.3M) | |
| Net Borrowings | (94.0M) | (522M) | 122M | 665M | 764.8M | 803.0M | |
| Total Cashflows From Investing Activities | (179.9M) | (158.5M) | (229.9M) | (1.2B) | (1.0B) | (991.7M) | |
| Change To Operating Activities | (59.0M) | (58.2M) | (168.1M) | (138.1M) | (124.3M) | (118.1M) | |
| Other Cashflows From Investing Activities | (14.4M) | 19.2M | (17.2M) | (1.0B) | (923.3M) | (877.1M) | |
| Change To Netincome | 97.1M | 74.4M | 85.9M | 60.3M | 69.4M | 65.8M | |
| Change To Liabilities | (23.4M) | 210.7M | (247.6M) | 31.3M | 28.2M | 24.6M | |
| Issuance Of Capital Stock | 48.2M | 37.8M | 47.4M | 49.1M | 53.1M | 49.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Resmed Stock Analysis
When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.